STOCK TITAN

[6-K] TotalEnergies SE Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) filed a Form 6-K disclosing the voting outcomes of its 149th Ordinary General Meeting of Shareholders held on 25 June 2025.

  • Dividend: Shareholders approved a year-end dividend of 98 JPY per share with 98.73% support (11,330,491 votes for vs. 49,100 against).
  • Board Elections: All ten director nominees—including CEO Christophe Weber—were elected. Support ranged from 77.88% (Weber) to 97.33% (Miki Tsusaka).
  • Director Bonuses: A total bonus pool of 460 million JPY for two Japan-based directors was approved with 67.41% support.

No other agenda items were presented, and all approvals met statutory thresholds. The filing is primarily informational, confirming continuity of Takeda’s leadership and cash-return policy.

Takeda Pharmaceutical Company Limited (TAK) ha presentato un Modulo 6-K comunicando i risultati delle votazioni della sua 149ª Assemblea Ordinaria degli Azionisti tenutasi il 25 giugno 2025.

  • Dividendo: Gli azionisti hanno approvato un dividendo di fine anno di 98 JPY per azione con il 98,73% di voti favorevoli (11.330.491 voti a favore contro 49.100 contrari).
  • Elezioni del Consiglio: Tutti e dieci i candidati a direttore, incluso l’Amministratore Delegato Christophe Weber, sono stati eletti. Il sostegno è variato dal 77,88% (Weber) al 97,33% (Miki Tsusaka).
  • Bonus ai Direttori: È stato approvato un fondo bonus totale di 460 milioni di JPY per due direttori con sede in Giappone con il 67,41% di voti favorevoli.

Non sono stati presentati altri punti all’ordine del giorno e tutte le approvazioni hanno rispettato le soglie statutarie. La comunicazione ha carattere principalmente informativo, confermando la continuità della leadership di Takeda e la politica di distribuzione di liquidità agli azionisti.

Takeda Pharmaceutical Company Limited (TAK) presentó un Formulario 6-K revelando los resultados de las votaciones de su 149ª Junta General Ordinaria de Accionistas celebrada el 25 de junio de 2025.

  • Dividendo: Los accionistas aprobaron un dividendo de fin de año de 98 JPY por acción con un apoyo del 98,73% (11.330.491 votos a favor frente a 49.100 en contra).
  • Elecciones del Consejo: Todos los diez candidatos a directores, incluido el CEO Christophe Weber, fueron elegidos. El apoyo varió desde el 77,88% (Weber) hasta el 97,33% (Miki Tsusaka).
  • Bonos para Directores: Se aprobó un fondo total de bonos de 460 millones de JPY para dos directores con sede en Japón con un apoyo del 67,41%.

No se presentaron otros puntos en la agenda y todas las aprobaciones cumplieron con los umbrales legales. La presentación es principalmente informativa, confirmando la continuidad del liderazgo de Takeda y su política de retorno de efectivo a los accionistas.

Takeda Pharmaceutical Company Limited (TAK)는 2025년 6월 25일에 개최된 제149차 정기 주주총회 투표 결과를 공개하는 Form 6-K를 제출했습니다.

  • 배당금: 주주들은 주당 98 JPY의 연말 배당을 98.73%의 찬성률(11,330,491표 찬성 대 49,100표 반대)로 승인했습니다.
  • 이사회 선거: CEO 크리스토프 웨버를 포함한 10명의 이사 후보 전원이 선출되었습니다. 지지율은 77.88%(웨버)에서 97.33%(미키 츠사카)까지 다양했습니다.
  • 이사 보너스: 일본 소재 이사 두 명에게 총 4억 6천만 JPY의 보너스 풀을 67.41%의 찬성으로 승인했습니다.

기타 안건은 없었으며 모든 승인 사항은 법적 기준을 충족했습니다. 이번 제출은 주로 정보 제공 목적이며, 다케다의 리더십과 현금 환원 정책의 지속성을 확인하는 내용입니다.

Takeda Pharmaceutical Company Limited (TAK) a déposé un formulaire 6-K divulguant les résultats des votes de sa 149e assemblée générale ordinaire des actionnaires tenue le 25 juin 2025.

  • Dividende : Les actionnaires ont approuvé un dividende de fin d'année de 98 JPY par action avec un soutien de 98,73 % (11 330 491 votes pour contre 49 100 contre).
  • Élections du conseil d'administration : Les dix candidats au poste d'administrateur, y compris le PDG Christophe Weber, ont été élus. Le soutien variait de 77,88 % (Weber) à 97,33 % (Miki Tsusaka).
  • Bonus des administrateurs : Un fonds total de bonus de 460 millions de JPY pour deux administrateurs basés au Japon a été approuvé avec 67,41 % de soutien.

Aucun autre point à l'ordre du jour n'a été présenté et toutes les approbations ont atteint les seuils légaux. Le dépôt est principalement informatif, confirmant la continuité du leadership de Takeda et sa politique de redistribution de liquidités.

Takeda Pharmaceutical Company Limited (TAK) hat ein Formular 6-K eingereicht, in dem die Abstimmungsergebnisse seiner 149. Ordentlichen Hauptversammlung der Aktionäre am 25. Juni 2025 bekanntgegeben wurden.

  • Dividende: Die Aktionäre stimmten einer Jahresenddividende von 98 JPY pro Aktie mit 98,73 % Zustimmung zu (11.330.491 Stimmen dafür vs. 49.100 dagegen).
  • Vorstandswahlen: Alle zehn vorgeschlagenen Direktoren, einschließlich CEO Christophe Weber, wurden gewählt. Die Unterstützung reichte von 77,88 % (Weber) bis 97,33 % (Miki Tsusaka).
  • Direktor-Boni: Ein Gesamtbonuspool von 460 Millionen JPY für zwei in Japan ansässige Direktoren wurde mit 67,41 % Zustimmung genehmigt.

Es wurden keine weiteren Tagesordnungspunkte vorgelegt, und alle Genehmigungen erfüllten die gesetzlichen Schwellenwerte. Die Einreichung dient hauptsächlich der Information und bestätigt die Kontinuität von Takedas Führung und der Dividendenpolitik.

Positive
  • Year-end dividend of 98 JPY per share approved with 98.73% support, reaffirming Takeda’s commitment to shareholder returns.
Negative
  • None.

Insights

TL;DR Routine AGM: dividend and all board proposals passed; solid but unremarkable governance outcome.

The decisive approval of all three proposals indicates shareholder alignment with management. Christophe Weber’s lower—but still strong—77.9% support suggests minor dissent yet well within best-practice thresholds. Approval of sizable bonuses at only 67.4% underscores growing scrutiny on executive pay, though passage avoids immediate governance risk. Overall, the meeting maintains board continuity and signals investor confidence.

TL;DR Dividend confirmation reinforces Takeda’s income profile; governance results pose no material strategic shift.

The 98 JPY dividend equates to roughly 2.2 % quarterly yield at recent prices, aligning with management’s commitment to stable returns. Director re-elections ensure strategic consistency around R&D pipeline execution and debt deleveraging. The approved bonus pool is immaterial relative to Takeda’s ¥4+ trillion revenue base. Hence, the filing is neutral-to-slightly-positive for income-focused investors but not a catalyst for valuation change.

Takeda Pharmaceutical Company Limited (TAK) ha presentato un Modulo 6-K comunicando i risultati delle votazioni della sua 149ª Assemblea Ordinaria degli Azionisti tenutasi il 25 giugno 2025.

  • Dividendo: Gli azionisti hanno approvato un dividendo di fine anno di 98 JPY per azione con il 98,73% di voti favorevoli (11.330.491 voti a favore contro 49.100 contrari).
  • Elezioni del Consiglio: Tutti e dieci i candidati a direttore, incluso l’Amministratore Delegato Christophe Weber, sono stati eletti. Il sostegno è variato dal 77,88% (Weber) al 97,33% (Miki Tsusaka).
  • Bonus ai Direttori: È stato approvato un fondo bonus totale di 460 milioni di JPY per due direttori con sede in Giappone con il 67,41% di voti favorevoli.

Non sono stati presentati altri punti all’ordine del giorno e tutte le approvazioni hanno rispettato le soglie statutarie. La comunicazione ha carattere principalmente informativo, confermando la continuità della leadership di Takeda e la politica di distribuzione di liquidità agli azionisti.

Takeda Pharmaceutical Company Limited (TAK) presentó un Formulario 6-K revelando los resultados de las votaciones de su 149ª Junta General Ordinaria de Accionistas celebrada el 25 de junio de 2025.

  • Dividendo: Los accionistas aprobaron un dividendo de fin de año de 98 JPY por acción con un apoyo del 98,73% (11.330.491 votos a favor frente a 49.100 en contra).
  • Elecciones del Consejo: Todos los diez candidatos a directores, incluido el CEO Christophe Weber, fueron elegidos. El apoyo varió desde el 77,88% (Weber) hasta el 97,33% (Miki Tsusaka).
  • Bonos para Directores: Se aprobó un fondo total de bonos de 460 millones de JPY para dos directores con sede en Japón con un apoyo del 67,41%.

No se presentaron otros puntos en la agenda y todas las aprobaciones cumplieron con los umbrales legales. La presentación es principalmente informativa, confirmando la continuidad del liderazgo de Takeda y su política de retorno de efectivo a los accionistas.

Takeda Pharmaceutical Company Limited (TAK)는 2025년 6월 25일에 개최된 제149차 정기 주주총회 투표 결과를 공개하는 Form 6-K를 제출했습니다.

  • 배당금: 주주들은 주당 98 JPY의 연말 배당을 98.73%의 찬성률(11,330,491표 찬성 대 49,100표 반대)로 승인했습니다.
  • 이사회 선거: CEO 크리스토프 웨버를 포함한 10명의 이사 후보 전원이 선출되었습니다. 지지율은 77.88%(웨버)에서 97.33%(미키 츠사카)까지 다양했습니다.
  • 이사 보너스: 일본 소재 이사 두 명에게 총 4억 6천만 JPY의 보너스 풀을 67.41%의 찬성으로 승인했습니다.

기타 안건은 없었으며 모든 승인 사항은 법적 기준을 충족했습니다. 이번 제출은 주로 정보 제공 목적이며, 다케다의 리더십과 현금 환원 정책의 지속성을 확인하는 내용입니다.

Takeda Pharmaceutical Company Limited (TAK) a déposé un formulaire 6-K divulguant les résultats des votes de sa 149e assemblée générale ordinaire des actionnaires tenue le 25 juin 2025.

  • Dividende : Les actionnaires ont approuvé un dividende de fin d'année de 98 JPY par action avec un soutien de 98,73 % (11 330 491 votes pour contre 49 100 contre).
  • Élections du conseil d'administration : Les dix candidats au poste d'administrateur, y compris le PDG Christophe Weber, ont été élus. Le soutien variait de 77,88 % (Weber) à 97,33 % (Miki Tsusaka).
  • Bonus des administrateurs : Un fonds total de bonus de 460 millions de JPY pour deux administrateurs basés au Japon a été approuvé avec 67,41 % de soutien.

Aucun autre point à l'ordre du jour n'a été présenté et toutes les approbations ont atteint les seuils légaux. Le dépôt est principalement informatif, confirmant la continuité du leadership de Takeda et sa politique de redistribution de liquidités.

Takeda Pharmaceutical Company Limited (TAK) hat ein Formular 6-K eingereicht, in dem die Abstimmungsergebnisse seiner 149. Ordentlichen Hauptversammlung der Aktionäre am 25. Juni 2025 bekanntgegeben wurden.

  • Dividende: Die Aktionäre stimmten einer Jahresenddividende von 98 JPY pro Aktie mit 98,73 % Zustimmung zu (11.330.491 Stimmen dafür vs. 49.100 dagegen).
  • Vorstandswahlen: Alle zehn vorgeschlagenen Direktoren, einschließlich CEO Christophe Weber, wurden gewählt. Die Unterstützung reichte von 77,88 % (Weber) bis 97,33 % (Miki Tsusaka).
  • Direktor-Boni: Ein Gesamtbonuspool von 460 Millionen JPY für zwei in Japan ansässige Direktoren wurde mit 67,41 % Zustimmung genehmigt.

Es wurden keine weiteren Tagesordnungspunkte vorgelegt, und alle Genehmigungen erfüllten die gesetzlichen Schwellenwerte. Die Einreichung dient hauptsächlich der Information und bestätigt die Kontinuität von Takedas Führung und der Dividendenpolitik.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

July 1st, 2025

Commission File Number 001-10888

 

 

 

TotalEnergies SE

(Translation of registrant’s name into English)

 

 

 

2, place Jean Millier

La Défense 6

92400 Courbevoie

France

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x        Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 

 

 

 

TotalEnergies SE is providing on this Form 6-K a description of certain recent developments relating to its business.

 

 

 

 

EXHIBIT INDEX

 

Exhibit No. Description
   
Exhibit 99.1 Disclosure of Transactions in Own Shares (June 2, 2025).
   
Exhibit 99.2 UK: TotalEnergies acquires a pipeline of solar and battery projects (June 3, 2025).
   
Exhibit 99.3 Brazil: TotalEnergies Increases its Interest in Lapa (June 4, 2025).
   
Exhibit 99.4 Capital increase reserved for employees of TotalEnergies in 2025 (June 10, 2025).
   
Exhibit 99.5 Disclosure of Transactions in Own Shares (June 10, 2025).
   
Exhibit 99.6 Gurīn Energy selects Saft’s battery energy storage system for first Japanese project (June 12, 2025).
   
Exhibit 99.7 TotalEnergies to Collaborate with Mistral AI to Increase the Application of Artificial Intelligence in its Multi-Energy Strategy (June 12, 2025).
   
Exhibit 99.8 TotalEnergies to Collaborate with Mistral AI to Increase the Application of Artificial Intelligence in its Multi-Energy Strategy (June 12, 2025).
   
Exhibit 99.9 United States: TotalEnergies enters 40 Chevron-operated exploration blocks, building on a successful U.S. offshore partnership between both Companies (June 16, 2025).
   
Exhibit 99.10 Paris Air Show: TotalEnergies, a pioneer in sustainable aviation fuels and committed to the decarbonization of air transport (June 16, 2025).
   
Exhibit 99.11 TotalEnergies Expands Malaysia’s Portfolio Strengthening its Strategic Partnership with PETRONAS (June 16, 2025).
   
Exhibit 99.12 Disclosure of Transactions in Own Shares (June 16, 2025).
   
Exhibit 99.13 Germany: TotalEnergies Awarded an Offshore Wind Concession in the North Sea (June 17, 2025).
   
Exhibit 99.14 Paris Air Show: TotalEnergies Signs a Deal with Quatra to Secure Feedstock for its Biorefineries (June 17, 2025).
   
Exhibit 99.15 Algeria: TotalEnergies is Granted a New Exploration License (June 17, 2025).
   
Exhibit 99.16 Disclosure of Transactions in Own Shares (June 23, 2025).
   
Exhibit 99.17 TotalEnergies becomes Official Partner of the Tour de France and specifies its cycling partnerships (June 26, 2025).
   
Exhibit 99.18 Suriname: TotalEnergies acquires 25% interest in Block 53 (June 27, 2025).
   
Exhibit 99.19 Disclosure of Transactions in Own Shares (June 30, 2025).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  TotalEnergies SE
     
     
Date: July 1st, 2025 By: /s/ DENIS TOULOUSE
    Name: Denis Toulouse
    Title: Company Treasurer

 

 

 

FAQ

What dividend per share did Takeda (TAK) shareholders approve?

Shareholders approved a year-end dividend of 98 JPY per common share.

When was Takeda’s 149th Annual General Meeting held?

The AGM took place on 25 June 2025.

Were all director nominees elected at the 2025 AGM?

Yes. All 10 nominees were elected with approval percentages ranging from 77.88 % to 97.33 %.

How much in director bonuses was approved at the AGM?

A bonus pool of 460 million JPY for two Japan-based directors was approved.

What was the shareholder approval rate for the dividend proposal?

Proposal No.1 (dividend) received 98.73 % shareholder support.

Which director received the lowest approval percentage?

CEO Christophe Weber received the lowest support at 77.88 %.
Totalenergies Se

NYSE:TTE

TTE Rankings

TTE Latest News

TTE Stock Data

134.55B
2.22B
0%
7.1%
0.19%
Oil & Gas Integrated
Energy
Link
France
Courbevoie